Wilk Michał, Waśko-Grabowska Anna, Szmit Sebastian
Department of Clinical Oncology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland.
Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland.
Front Pharmacol. 2020 Dec 22;11:555475. doi: 10.3389/fphar.2020.555475. eCollection 2020.
Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. In recent years, numerous novel therapeutics that improve survival and ameliorate disease control have been approved. Currently, the systemic treatment for prostate neoplasm consists of hormonal therapy, chemotherapy, immunotherapy, radiopharmaceuticals, targeted therapy, and supportive agents (e.g., related to bone health). Unfortunately, many of them carry a risk of cardiovascular complications, which occasionally pose a higher mortality threat than cancer itself. This article provides a unique and comprehensive overview of the prevalence and possible mechanisms of cardiovascular toxicities of all PC therapies, including state-of-the-art antineoplastic agents. Additionally, this article summarizes available recommendations regarding screening and prevention of the most common cardiac complications among patients with advanced cancer disease.
前列腺癌（PC）的治疗是药理学研究中一个快速发展的领域。近年来，许多能够提高生存率并改善疾病控制的新型疗法已获批准。目前，前列腺肿瘤的全身治疗包括激素疗法、化疗、免疫疗法、放射性药物、靶向疗法和支持性药物（例如与骨骼健康相关的药物）。不幸的是，其中许多疗法都有心血管并发症的风险，这些并发症偶尔会带来比癌症本身更高的死亡威胁。本文对所有PC治疗方法（包括最新的抗肿瘤药物）心血管毒性的发生率和可能机制进行了独特而全面的概述。此外，本文总结了关于晚期癌症患者中最常见心脏并发症的筛查和预防的现有建议。
